Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.

Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP.

Hematology. 2012 Apr;17 Suppl 1:S90-2. doi: 10.1179/102453312X13336169155970.

PMID:
22507790
2.

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP.

Cancer. 2008 May 15;112(10):2228-32. doi: 10.1002/cncr.23422.

3.

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T.

Leuk Lymphoma. 2008 Mar;49(3):447-50. doi: 10.1080/10428190701837330.

PMID:
18297520
4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
5.

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.

Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP.

Cancer. 2010 Jun 1;116(11):2655-64. doi: 10.1002/cncr.25055.

6.

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.

Cancer J. 2000 May-Jun;6(3):146-50.

PMID:
10882329
7.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group.

J Clin Oncol. 2003 May 1;21(9):1734-9.

PMID:
12721249
8.

Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.

Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM.

Blood. 1981 Nov;58(5):920-5.

9.

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.

Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E.

Br J Haematol. 2002 Jan;116(1):229-35.

PMID:
11841421
10.

[Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].

Huang HQ, Jiang WQ, Wang W, Zhou ZM, Xia ZJ, Lin XB, Li YH, Xu RH, Zhang L, Xu GC, Sun XF, Liu DG, He YJ, Guan ZZ.

Ai Zheng. 2003 Apr;22(4):389-92. Chinese.

PMID:
12703995
11.

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.

Clin Cancer Res. 2006 Sep 1;12(17):5190-8.

12.

Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.

Cabanillas F, Burgess MA, Bodey GP, Freireich EJ.

Am J Med. 1983 Mar;74(3):382-8.

PMID:
6187213
14.

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI.

J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21.

PMID:
20026801
15.
16.

[Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].

Klein HO.

Hamatol Bluttransfus. 1976;18:135-45. German. No abstract available.

PMID:
786808
17.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Müller U, Loeffler M.

Blood. 1998 Dec 15;92(12):4560-7.

18.

[Therapy of non-Hodgkin lymphomas].

Izzi T, Porcellini A, Delfini C, Lucarelli G.

Minerva Med. 1982 Apr 7;73(15):949-53. Italian. No abstract available.

PMID:
7078792
19.

European experience with ifosfamide in lymphomas.

von Kalle AK, Schaadt M, Diehl V.

Semin Oncol. 1989 Feb;16(1 Suppl 3):73-7. Review.

PMID:
2468184
20.

VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.

Hansen MM, Bloomfield CD, Jørgensen J, Ersbøll J, Pedersen-Bjergaard J, Blom J, Nissen NI.

Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1135-7.

PMID:
7459900

Supplemental Content

Support Center